The Top 3 Stocks to Watch in May 2019

The Top 3 Stocks to Watch in May 2019

If you really want to become a better investor then you need to be looking at where the smart money is heading.  You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream.

That’s how the long-term wealth can be found.

For example, in January 2019, we noted that Fate Therapeutics (FATE) was a great opportunity at $12 a share. It’s now up to $16.32.

We also highlighted Glu Mobile (GLUU) around $7.75.  It’s now up to $11.

Today, we’ve uncovered three stocks that have the same potential.

Small Cap Bargain No. 1—Geron Corporation (NASDAQ:GERN)

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

This is a small biotech with a large amount of cash and two products in FDA trials.

At the moment, the company has $164.29 million in cash. Two, the company is developing a first-in-class inhibitor, imetelstat, for patients afflicted with a blood-based malignancy, known as lower risk myelodysplastic syndromes (MDS). The company believes this treatment could generate sales of more than $500 million. That’s quite a potential payday for a company with a market cap of $354.17 million.

Geron expects to initiate a Phase III study in low-risk MDS this year. The treatment has already demonstrated efficacy in myelofibrosis, or MF patients that have not done as well with other drugs. Analysts at Needham believe the treatment creates a buying opportunity, and has given the stock a price target of $3 a share.

Small Cap Bargain No. 2 — TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.

Biotech is always an exciting trade. And from what we can see from TGTX study data, this stock could be just as exciting. In a mid-stage trial for refractory marginal zone lymphoma (MZL), the drug easily met its primary endpoint of overall response rate. The FDA also just granted umbralisib a Breakthrough Therapy Designation for the treatment.

Even better, the drug is currently showing a favorable efficacy when compared to other drugs, including an AbbVie drug treatment. Should all go according to plan, the company could be on track to see a few hundred million dollars in annual sales. Plus, takeover chatter on TG Therapeutics (TGTX) is beginning to build again. Cantor Fitzgerald analysts have a price target of $17 on the stock.

Small Cap Bargain No. 3 — Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) in the United States and Poland. The company’s flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous Tcell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers.

The company announced that its ongoing research at The University of Texas Anderson Cancer Center has shown that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animals.

“We know that Annamycin was previously shown to be significantly more potent than doxorubicin in both Lewis lung carcinoma in vivo and small cell lung cancer in vitro models,” said Walter Klemp, Moleculin’s Chairman and CEO.

“Now we are seeing significant activity against triple negative breast cancer that has metastasized to the lungs. This particular animal model used in our testing is considered to represent a very aggressive form of cancer. We believe our success in increasing the survival rate in mice with this tumor model in combination with the previously observed high uptake of Annamycin by the lungs is a promising indication that supports additional clinical research in lung and metastatic lung cancers.”

The company also announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors. “WP1066 was shown to have a significant anti-tumor effect on medulloblastoma cell lines, so there is a lot of encouragement regarding the opportunity to provide new hope for treating this rare condition,” added Klemp.

In Conclusion

Again, if you really want to become a better investor then you need to be looking at where the smart money is heading.  You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream.

That’s how the long-term wealth can be found.  And we believe these four stocks above can offer that long-term.

Disclaimer

This manual is for informational and entertainment purposes only. The author is not an investment adviser, financial adviser, or broker, and the material contained herein is not intended as investment advice. If you wish to obtain personalized investment advice, you should consult with a Certified Financial Planner (CFP). All statements made in this manual are based on the author’s own opinion. Neither the author or the publisher warrants or assume any responsibility for the accuracy of the statements or information contained in this manual, and specifically disclaims the accuracy of any data, including stock prices and stock performance histories. No mention of a particular security or instrument herein constitutes a recommendation to buy or sell that or any security or instrument, nor does it mean that any particular security, instrument, portfolio of securities, transaction or investment strategy is suitable for any specific individual. Neither the author or the publisher, can assess, verify, or guarantee the accuracy, adequacy, or completeness of any information, the suitability or profitability of any particular investment or methodology, or the potential value of any investment or informational source. READERS BEAR THE SOLE RESPONSIBILITY FOR THEIR OWN INVESTMENT DECISIONS. NEITHER THE AUTHOR OR THE PUBLISHER IS RESPONSIBLE FOR ANY LOSSES DUE TO INVESTMENT DECISIONS MADE BASED ON INFORMATION PROVIDED HEREIN. At the time of writing, neither the author or the publisher has a position in any of the stocks mentioned in this manual.